Exane Derivatives’s Constellium CSTM Stock Holding History

Exane Derivatives’s Portfolio CSTM Stock Details CSTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$370	Sell	28 -3,331	-99%	-$53.2K	﹤0.01%	603
2022 Q1	$60.5K	Buy	+3,359	New	+$61.3K	0.02%	549

Other funds holding CSTM

Bpifrance Maisons Alfort, Cedex, France $1.36B AUM 21.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

NTCM

Nut Tree Capital Management New York $419M AUM 65.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Robeco Schweiz Zurich, Switzerland $6.23B AUM 86.54% 1-Year Est. Return

Exane Derivatives's CSTM Position: Q2 2022 in Review

Exane Derivatives reduced its Constellium (CSTM) stake by 99% in Q2 2022, selling an estimated $53.2K and leaving 28 shares worth $370. The position accounts for ﹤0.01% of the portfolio, ranked #603.

Exane Derivatives first reported a position in CSTM in Q1 2022 and has held it in 2 quarters since. The position peaked at $60.5K in Q1 2022. 188 funds tracked by Wall St. Rank hold CSTM as of Q2 2022.

Exane Derivatives held 28 shares of Constellium worth $370 as of Q2 2022.
Exane Derivatives sold 3,331 Constellium shares in Q2 2022, an estimated $53.2K.
Constellium made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #603 holding.
Exane Derivatives first reported a position in Constellium in Q1 2022 and has held it in 2 quarters since.
Exane Derivatives's Constellium position peaked at $60.5K in Q1 2022.
188 funds tracked by Wall St. Rank held Constellium as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.